Sensei Biotherapeutics Inc.

07/09/2025 | Press release | Distributed by Public on 07/09/2025 14:31

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 2, 2025, Sensei Biotherapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Staff has determined that for 10 consecutive business days, from June 17, 2025 to July 1, 2025, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

2

Sensei Biotherapeutics Inc. published this content on July 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on July 09, 2025 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io